|
1
|
Finn OJ: Immuno-oncology: Understanding
the function and dysfunction of the immune system in cancer. Ann
Oncol. 23 Suppl 8:viii6–viii9. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Marabelle A, Kohrt H, Caux C and Levy R:
Intratumoral immunization: A new paradigm for cancer therapy. Clin
Cancer Res. 20:1747–1756. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Turtle CJ, Hudecek M, Jensen MC and
Riddell SR: Engineered T cells for anti cancer therapy. Curr Opin
Immunol. 24:633–639. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Poirier N, Blancho G and Vanhove B: A more
selective costimulatory blockade of the CD28-B7 pathway. Transpl
Int. 24:2–11. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maj T, Wei S, Welling T and Zou W: T cells
and costimulation in cancer. Cancer J. 19:473–482. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chapoval AI, Ni J, Lau JS, Wilcox RA,
Flies DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K and Chen L:
B7-H3: A costimulatory molecule for T cell activation and IFN-gamma
production. Nat Immunol. 2:269–274. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Suh WK, Gajewska BU, Okada H, Gronski MA,
Bertram EM, Dawicki W, Duncan GS, Bukczynski J, Plyte S, Elia A, et
al: The B7 family member B7-H3 preferentially down regulates T
helper type 1-mediated immune responses. Nat Immunol. 4:899–906.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang L, Kang FB and Shan BE:
B7-H3-mediated tumor immunology: Friend or foe? Int J Cancer.
134:2764–2771. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hashiguchi M, Kobori H, Ritprajak P,
Kamimura Y, Kozono H and Azuma M: Triggering receptor expressed on
myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for
B7-H3 and enhances T cell responses. Proc Natl Acad Sci USA.
105:10495–10500. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Loos M, Hedderich DM, Friess H and Kleeff
J: B7-h3 and its role in antitumor immunity. Clin Dev Immunol.
2010:6838752010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Riabov V, Gudima A, Wang N, Mickley A,
Orekhov A and Kzhyshkowska J: Role of tumor associated macrophages
in tumor angiogenesis and lymphangiogenesis. Front Physiol.
5:752014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lewis CE and Pollard JW: Distinct role of
macrophages in different tumor microenvironments. Cancer Res.
66:605–612. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bingle L, Brown NJ and Lewis CE: The role
of tumor-associated macrophages in tumor progression: Implications
for new anticancer therapies. J Pathol. 196:254–265. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Karnevi E, Andersson R and Rosendahl AH:
Tumour-educated macrophages display a mixed polarisation and
enhance pancreatic cancer cell invasion. Immunol Cell Biol.
92:543–552. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou W and Bao S: Reciprocal supportive
interplay between glioblastoma and tumor-associated macrophages.
Cancers (Basel). 6:723–740. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gordon S and Taylor PR: Monocyte and
macrophage heterogeneity. Nat Rev Immunol. 5:953–964. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mantovani A, Sica A, Sozzani S, Allavena
P, Vecchi A and Locati M: The chemokine system in diverse forms of
macrophage activation and polarization. Trends Immunol. 25:677–686.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mosser DM and Edwards JP: Exploring the
full spectrum of macrophage activation. Nat Rev Immunol. 8:958–969.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hagemann T, Wilson J, Burke F, Kulbe H, Li
NF, Plüddemann A, Charles K, Gordon S and Balkwill FR: Ovarian
cancer cells polarize macrophages toward a tumor-associated
phenotype. J Immunol. 176:5023–5032. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sica A, Schioppa T, Mantovani A and
Allavena P: Tumor-associated macrophages are a distinct M2
polarised population promoting tumor progression: Potential targets
of anti-cancer therapy. Eur J Cancer. 42:717–727. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mantovani A, Allavena P and Sica A:
Tumor-associated macrophages as a prototypic type II polarised
phagocyte population: Role in tumor progression. Eur J Cancer.
40:1660–1667. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Weitz J, Koch M, Debus J, Höhler T, Galle
PR and Büchler MW: Colorectal cancer. Lancet. 365:153–165. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dong ZW QY, Li LD, Chen YD, Wang RT and
Lei TH: Report of Chinese cancer control strategy. Chin Cancer.
11:250–60. 2002.
|
|
24
|
Sun J, Chen LJ, Zhang GB, Jiang JT, Zhu M,
Tan Y, Wang HT, Lu BF and Zhang XG: Clinical significance and
regulation of the costimulatory molecule B7-H3 in human colorectal
carcinoma. Cancer Immunol Immunother. 59:1163–1171. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hammes LS, Tekmal RR, Naud P, Edelweiss
MI, Kirma N, Valente PT, Syrjänen KJ and Cunha-Filho JS:
Up-regulation of VEGF, c-fms and COX-2 expression correlates with
severity of cervical cancer precursor (CIN) lesions and invasive
disease. Gynecol Oncol. 110:445–451. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen LJ, Sun J, Wu HY, Zhou SM, Tan Y, Tan
M, Shan BE, Lu BF and Zhang XG: B7-H4 expression associates with
cancer progression and predicts patient's survival in human
esophageal squamous cell carcinoma. Cancer Immunol Immunother.
60:1047–1055. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Flies DB and Chen L: Modulation of immune
response by B7 family molecules in tumor microenvironments. Immunol
Invest. 35:395–418. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schietinger A and Greenberg PD: Tolerance
and exhaustion: Defining mechanisms of T cell dysfunction. Trends
Immunol. 35:51–60. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fourcade J, Sun Z, Pagliano O, Guillaume
P, Luescher IF, Sander C, Kirkwood JM, Olive D, Kuchroo V and
Zarour HM: CD8(+) T cells specific for tumor antigens can be
rendered dysfunctional by the tumor microenvironment through
up-regulation of the inhibitory receptors BTLA and PD-1. Cancer
Res. 72:887–896. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Leek RD and Harris AL: Tumor-associated
macrophages in breast cancer. J Mammary Gland Biol Neoplasia.
7:177–189. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hagemann T, Wilson J, Burke F, Kulbe H, Li
NF, Plüddemann A, Charles K, Gordon S and Balkwill FR: Ovarian
cancer cells polarize macrophages toward a tumor-associated
phenotype. J Immunol. 176:5023–5032. 2006. View Article : Google Scholar : PubMed/NCBI
|
